Media ReleasesImpediMed

View All ImpediMed News

ImpediMed - HFSA Abstracts Demonstrate Utility of SOZO for HF Patients

ImpediMed Limited (ASX.IPD) today announced two abstracts are being presented in the poster session of the prestigious Heart Failure Society of America (HFSA) Annual Scientific Meeting September 10 – 13, 2021. The abstracts were from studies conducted at Scripps Memorial Hospital campuses and were accepted in the Clinical Care category.

The abstracts were as follows:

Time to decongestion following heart failure hospitalisation as measured by extracellular fluid nadir using bioimpedance spectroscopy (BIS).

This was a multi-centre observational study evaluating volume status of heart failure patients recently discharged from hospital and undergoing a diuretic regimen, with reducing extracellular fluid (ECF) being the main objective of the therapy. The study undertook daily SOZO® BIS measurements to track fluid status and compared them to corresponding weight measurements. It took an average of 16.9 days for patients to reach their lowest extracellular fluid volume following a heart failure-related hospital stay. During this time, patients experienced more than a two-fold ECF loss as compared to weight loss on a percentage basis, demonstrating the sensitivity of BIS as diuretic decongestion reduces ECF.

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.